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Abstract
The transcription factor GATA-3, highly expressed in many cutaneous T-cell lymphoma (CTCL) and
peripheral T-cell lymphomas (PTCL), confers resistance to chemotherapy in a cell-autonomous man-
ner. As GATA-3 is transcriptionally regulated by NF-jB, we sought to determine the extent to which
proteasomal inhibition impairs NF-jB activation and GATA-3 expression and cell viability in malig-
nant T cells. Proteasome inhibition, NF-jB activity, GATA-3 expression, and cell viability were
examined in patient-derived cell lines and primary T-cell lymphoma specimens ex vivo treated with
the oral proteasome inhibitor ixazomib. Significant reductions in cell viability, NF-jB activation, and
GATA-3 expression were observed preclinically in ixazomib-treated cells. Therefore, an investigator-
initiated, single-center, phase II study with this agent in patients with relapsed/refractory CTCL/
PTCL was conducted. Concordant with our preclinical observations, a significant reduction in NF-jB
activation and GATA-3 expression was observed in an exceptional responder following one month
of treatment with ixazomib. While ixazomib had limited activity in this small and heterogeneous
cohort of patients, inhibition of the NF-jB/GATA-3 axis in a single exceptional responder suggests
that ixazomib may have utility in appropriately selected patients or in combination with other agents.
1 | INTRODUCTION
The T-cell lymphomas (TCLs) are a molecularly and clinically heteroge-
neous group of non-Hodgkin’s lymphomas (NHL) that are often resist-
ant to conventional chemotherapeutic regimens. Mycosis fungoides
(MF), the most common cutaneous T-cell lymphoma (CTCL) subtype,
commonly presents with limited-stage disease and is managed with
skin-directed therapies.1 Survival in these patients is measured in years
to decades, with survival for those with less than 10% body surface
area involvement comparable to that observed in age-matched subjects
without CTCL.1 In contrast, patients with advanced-stage disease, or
limited-stage disease unresponsive to skin-directed therapies, require
systemic therapy. While responses to conventional chemotherapeutic
agents may be achieved, these responses are short-lived, likely
secondary to inherent resistance mechanisms that are incompletely
understood.2,3 In North America, the most common peripheral T-cell
lymphoma (PTCL) remains “not otherwise specified (NOS).”4 Among
PTCL, NOS patients with relapsed/refractory disease who are not
eligible for hematopoietic stem-cell transplantation, novel therapies are
not curative, rarely achieve a durable remission, and are effective in
only a subset of patients.5,6 Therefore, novel therapies are needed for
the TCLs, and clinical trial participation is encouraged.
The mechanisms underlying primary and acquired resistance to
conventional or novel chemotherapeutic agents in CTCL and PTCL are
poorly understood. Recurrent somatic alterations (eg, PLC-g1 muta-
tions7 and NF-jB truncations8,9), genomic losses (eg, including p531,9)
and the expression of multidrug resistance proteins likely contribute to
resistance.10 Constituents of the tumor microenvironment, particularly
lymphoma-associated macrophages, may also promote resistance to
chemotherapy,11 likely due to the provision of cell surface ligands or
cytokines that activate signaling pathways implicated in chemotherapy
resistance (reviewed in Ref. 12). A limited number of transcriptional
regulators known to regulate the differentiation, proliferation,
and survival of normal T cells have also been implicated in disease
pathogenesis and chemotherapy resistance, chief among these is the
NF-jB family of transcription factors.13–15 Constitutive NF-jBPhilip S. Boonstra and Avery Polk contributed equally to this study.
Am J Hematol. 2017;92:1287–1294. wileyonlinelibrary.com/journal/ajh VC 2017Wiley Periodicals, Inc. | 1287
Received: 16 June 2017 | Revised: 9 August 2017 | Accepted: 22 August 2017
DOI: 10.1002/ajh.24895
AJH
activation is frequently observed among the TCLs,15 and its inhibition
overcomes resistance to apoptosis.13,14 Furthermore, factors with a
known or suspected role in chemotherapy resistance are transcription-
ally regulated by NF-jB, including the transcription factor GATA-3.16
GATA-3, while frequently described as the “master regulator” of Th2
differentiation, is widely expressed, albeit to varying degrees, in most
T-cell subsets, where it not only regulates the expression of a vast
number of genes in a cell-type specific manner,17 but also promotes
T-cell survival.18 Notably, GATA-3 is highly expressed in both CTCL
and in a recently described subset of PTCL, NOS,19,20 (reviewed in Ref.
21). In these TCLs, GATA-3 promotes the production of Th2-
associated cytokines,19 including those that regulate the growth and
survival of malignant T cells.22 More recently, GATA-3 was shown to
promote resistance to chemotherapy in a cell-autonomous manner,
possibly explaining the high rate (>50%) of primary refractory disease
observed among GATA-31 PTCL, NOS.16 Therefore, the development
of therapeutic strategies targeting NF-jB and its target genes, including
GATA-3, are warranted. It is with that goal in mind that we sought to
investigate the novel proteasome inhibitor ixazomib (MLN9708).
The ubiquitin-proteasome pathway (UPP) plays a critically impor-
tant role in cell homeostasis and its inhibition has emerged as a promis-
ing therapeutic approach in hematologic malignancies. Proteasomal
inhibition, among its other effects, culminates in the inhibition of NF-
jB activity in TCLs.14 Limited experience with the proteasome inhibitor
bortezomib in CTCL is encouraging, as an overall response rate of 67%
was observed in a small phase II study.23 Furthermore, more recent evi-
dence suggests that novel agents currently approved for the treatment
of CTCL or under investigation also target the UPP.24 Therefore,
we sought to investigate the safety and efficacy of ixazomib, an oral
proteasome inhibitor, in relapsed/refractory cutaneous and PTCLs.
2 | MATERIALS AND METHODS
2.1 | Cell culture, viability assays, and reagents
Primary TCL cells were obtained from patients at the University of
Michigan Comprehensive Cancer Center, Ann Arbor, Michigan upon
approval by the Institutional Review Board (IRB) of the University
of Michigan, in accordance with U.S. Federal Regulations and the
Declaration of Helsinki. Primary TCL cells were purified, as previously
described.16 The TCL cell lines (T8ML-1, H9, and MyLa) used in this
study were mycoplasma free and independently validated, as previously
described.16,19,25 Primary cells and cell lines were grown at 378C in 5%
CO2 in RPMI 1640 (Life Technologies, Carlsbad, California) supple-
mented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville,
Georgia), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 1 mM L-glutamine, 50 IU/mL penicillin, and 50 mg/mL strepto-
mycin. For T8ML-1, 100 IU/mL recombinant human IL-2 was also
added. To engage T-cell receptor signaling, anti-CD3/CD28 Dynabeads
(Life Technologies) were cocultured with TCL cells. Ixazomib was
obtained from Selleckchem (Houston, Texas). Proteasomal inhibition
was examined by western blotting for total ubiquitin and b-catenin, as
previously described.16 Nuclear localization of NF-kB was determined
by western blot and deoxyribonucleic acid (DNA) binding examined by
enzyme-linked immunosorbant assay (ELISA), as previously described.16
GATA-3 expression was examined by western blot or flow cytometry,
as previously described.19 Cell viability and apoptosis were examined by
Annexin V/propidium iodide staining, as previously described.11
2.2 | Immunohistochemistry
Formalin-fixed, paraffin embedded diagnostic biopsy specimens were
immunohistochemically stained, as previously described,16,19 using the
DAKO Autostainer (DAKO, Carpinteria, California) and the FLEX HRP
EnVision System with diaminobenzadine as the chromogen. Heat
induced epitope retrieval was performed with FLEX TRS High pH
Retrieval Buffer for 20 min (DAKO, Carpinteria, California). An appro-
priate positive control (H9 xenograft16) was stained in parallel. Serial
tissue sections were incubated with anti-GATA3 antibody (Santa Cruz
Biotechnology, Dallas, Texas; clone HG3–35, 1:50) or anti-NF-jB (p65)
antibody (Cell Signaling Technology, Danvers, Massachusetts; clone
D14E12, 1:800) overnight at 48C after peroxidase blocking. Cases were
reviewed in a blinded fashion by a dermatopathologist (A.H.) or hem-
atopathologist (N.B., N.G.B.). Slides were viewed with an Olympus
BX51 microscope and pictures taken with an Olympus DP71 camera
(OCA, Center Valley, Pennsylvania). Olympus BSW with DP Control-
ler software was used for image acquisition and storage.
2.3 | Patients
This study was an open-label, single-center phase II study of ixazomib
in patients with relapsed or refractory cutaneous and PTCLs
(NCT02158975). Eligible patients were age 18 years with histologi-
cally confirmed TCL, including PTCL, NOS, angioimmunoblastic T-cell
lymphoma (AITL), ALK1 anaplastic large cell lymphoma (ALCL, ALK1),
ALK- ALCL (ALCL, ALK2), mycosis fungoides (MF), or Sezary syndrome
(SS). CTCL patients had stage IIb-IV disease.26 Patients had relapsed or
refractory disease after 1 prior systemic therapy (including extracor-
poreal photopheresis) and were 90 days from autologous stem-cell
transplantation. Performance status 0 to 2, and adequate hematologic,
hepatic, and renal function, including an absolute neutrophil count
1000/mL, were also required. Patients previously treated with borte-
zomib or with any serious medical comorbidity, including grade
3 peripheral neuropathy (or grade 2 peripheral neuropathy with pain
on physical examination), or active infection were excluded.
2.4 | Treatment and clinical endpoints
Patients received ixazomib monotherapy (4 mg) orally on a weekly
schedule (days 1, 8, and 15) every 28 days. Treatment was continued
until disease progression, unacceptable toxicity, or patient or investiga-
tor decision. Two dose reductions for toxicity were permitted. Patients
who failed to complete a cycle of treatment for any reason other than
disease progression were replaced.
The primary endpoint was best objective response, encompassing
complete response (CR), unconfirmed complete response (CRu), or par-
tial reseponse (PR), by the end of cycle 6, based on the investigators’
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response assessment. Patients unable to receive at least 2 cycles of ixa-
zomib with an accompanying response assessment were considered
treatment failures. Response assessments were determined using the
revised response criteria in malignant lymphoma for PTCL patients.27
Radiographic response assessments (positron emission tomography
[PET]/computed tomography [CT]) were performed after cycle 2, cycle
4, and cycle 6, and every three months thereafter until 24 months after
initiation of study treatment. Secondary response endpoints included
patient survival from start of treatment, both progression-free and
overall, and duration of response (DoR).
MF/SS response and progression were assessed in accordance with
the response criteria recommended by the International Society of Cuta-
neous Lymphoma, the United States Cutaneous Lymphoma Consortium
(USCLC) and the Cutaneous Lymphoma Task Force of the European
Organization for Research and Treatment of Cancer.28 Response in the
skin, blood (for patients with blood involvement at enrollment), lymph
nodes, and viscera were performed after cycle 2, cycle 4, and cycle 6, and
every three months thereafter until 24 months after initiation of study
treatment. Secondary endpoints included safety, tolerability, DoR,
progression-free survival (PFS), and overall survival (OS). GATA-3 expres-
sion, determined by immunohistochemistry,19 was explored as both a
predictive and pharmacodynamic biomarker.
Secondary endpoints were safety assessments, including history
and physical examination, and laboratory and adverse event (AE) moni-
toring. Toxicity and AE were graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events (version 4.0), and
regularly monitored by the University of Michigan Comprehensive
Cancer Center Data and Safety Monitoring Board.
2.5 | Trial design and statistical analysis
We used a two-stage design with an interim futility analysis.29 The pos-
ited “null” best objective response rate (ORR) was 30%. Given the pre-
viously reported ORR with bortezomib the trial was powered to detect
an improved ORR of 60% with probability .90, based upon a two-sided
type I error equal to .10.23 Subject to these statistical constraints and a
preplanned enrollment of 25 patients in total, we identified appropriate
rules for the interim and final analyses. Specifically, the interim analysis
would occur after an initial 11 patients were enrolled and followed for
response (the first stage); the trial would continue only if at least 4/11
patients exhibit objective response. In this case, the trial would accrue
an additional 14 patients (the second stage), and declare in favor of an
improved ORR if at least 12/25 patients exhibit objective response.
The study protocol was approved by the IRB and was conducted
in accordance with Good Clinical Practice, including written informed
consent and data monitoring.
3 | RESULTS
3.1 | Ixazomib inhibits the proteasome and impairs
cell viability in TCLs
CTCL (H9 and MyLa) and PTCL, NOS (T8ML-1) cell lines were incubated
with ixazomib and expression of ubiquitin and b-catenin examined in total
cell lysates (Figure 1A). Not surprisingly, brief exposure to ixazomib was
associated with a robust increase in total ubiquitin and b-catenin, consist-
ent with significant inhibition of the proteasome. Cell viability following
ixazomib treatment was examined in a standard 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay (data not shown) and by
Annexin V/propidium iodide staining (Figure 1B,C). A significant reduction
in cell viability and the induction of apoptosis in treated cells was
observed. Similarly designed experiments were performed in primary
CTCL (Sezary Syndrome) specimens ex vivo (Figure 1D,E), and a time-
dependent and dose-dependent reduction in cell viability was noted.
Nuclear translocation of NF-kB is facilitated by proteasome-
dependent degradation of cytoplasmic IjB. Therefore, we examined the
extent to which ixazomib impaired NF-jB nuclear translocation (Supple-
mentary Figure 1A) and DNA binding (Supplementary Figure 1B) in CTCL
cell lines. A significant reduction in NF-jB activation was observed. We
have previously demonstrated that the T-cell transcription factor GATA-3
is expressed in CTCL and PTCL,19 including a molecularly defined subset
of PTCL, NOS.19,30 Furthermore, GATA-3 confers resistance to chemo-
therapy in these TCL in a cell-autonomous manner and its expression is,
at least partially, NF-jB dependent.16 Therefore, we hypothesized that
ixazomib-mediated NF-jB inhibition may be associated with diminished
GATA-3 expression. Within 3 hour of ixazomib exposure a modest
increase in GATA-3 expression was observed (Supplementary Figure 1C),
consistent with its UPP-mediated degradation,31 (and data not shown).
However, within 24 hour of ixazomib treatment, a time point at which
NF-kB activation is significantly impaired (Supplementary Figure 1A,B), a
significant reduction in GATA-3 expression was observed (Supplementary
Figure 1C). GATA-3 expression was examined by intracellular flow
cytometry in primary CTCL (Sezary Syndrome) samples. A significant
reduction in GATA-3 expression was observed, particularly among speci-
mens that highly expressed GATA-3 (Supplementary Figure 1D,E). Collec-
tively, this data demonstrates that ixazomib impairs NF-jB activation and
GATA-3 expression and is directly cytotoxic to malignant T cells at clini-
cally achievable concentrations. Therefore, we launched an investigator-
initiated phase II study with this agent in relapsed/refractory TCLs.
3.2 | Patient characteristics
Between November 2014 and July 2016, 13 patients with relapsed or
refractory CTCL or PTCL were enrolled. Per protocol, two patients
who enrolled but did not finish at least one cycle were replaced;
however, one of the replaced patients received greater than 1 dose of
therapy and was thus included for response assessment, leaving a total
of 12 analyzable patients. All patients had histologically confirmed
CTCL (n55) or PTCL (n57, Table 1). A majority (10/12) of patients
were Caucasian, 9/12 were men, and the median age was 70 years
(range, 55–74 years). Evaluable patients received a median of 1 (range
1–3) prior systemic therapies, and 4/12 received prior radiotherapy.
Additional patient characteristics are summarized in Table 1.
3.3 | Efficacy
The observed ORRs at the interim analysis were 0% (0/5; 95% confi-
dence interval (CI) 0%, 43%) and 14% (1/7; 95% CI 2.6%, 51%) for
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CTCL and PTCL patients, respectively (Figure 2). One PTCL, NOS
patient (patient #006) achieved a CR. Combining histologies, the ORR
was 8% (95% CI 1.5%, 35%). Stable disease was observed in 6 patients
(50%). Five patients (4 with CTCL and stable disease) withdrew from
the study due to patient and/or investigator decision secondary to a
perceived lack of benefit and/or mild toxicity. The trial was stopped for
futility at the planned interim analysis. The single responding patient
(patient #006) achieved a PR at the time of the first response assess-
ment (Figure 3A), and ultimately achieved a CR (Figure 3A). Intranuclear
NF-jB (p65) and GATA-3 were examined semiquantitatively by immu-
nohistochemistry in paired pretreatment and post-treatment biopsies.
A loss of intranuclear NF-jB and partial inhibition of total GATA-3
expression was observed in this patient (Figure 3B). A similar reduction
in intranuclear NF-jB or GATA-3 was not observed in the remaining
patients who underwent a biopsy (n59) while on treatment (data not
shown). Six patients were on study for less than 2.5 months, and two
patients had follow-up exceeding five months. Five patients were cen-
sored for PFS at their time of withdrawal; for OS, patients who were
alive at the time of database lock (March 31, 2017) were administra-
tively censored (Supplementary Figure 2). The estimated median PFS
time was 3.2 months (95% CI 1.6, not reached). Five patients died
between start of treatment and database lock. A median OS time could
not be estimated; the lower bound of the 95% CI was 8.1 months. The
estimated OS rate at 12 months was approximately 60%.
3.4 | Safety
Overall, ixazomib was well tolerated, as few serious, drug-related AEs
were observed (Supplementary Table 1). No significant myelosuppres-
sion was observed, and hematologic toxicity was rare, occurring in less
than 10% of patients. As anticipated, the most common AEs were nau-
sea/vomiting and peripheral neuropathy, all of which were mild
(<grade 3). A single CTCL patient developed secondary impetiginiza-
tion (Staphylococcus aureaus and Pseudomonas aeruginosa) that was
subsequently complicated by sepsis (grade 4) and respiratory failure
(grade 5) within 30 days of treatment discontinuation. AEs by patient
are graphically summarized in Supplementary Figure 3.
4 | DISCUSSION
Novel therapeutic strategies are needed for patients with relapsed or
refractory TCLs, as few complete and durable remissions are achieved
FIGURE 1 Ixazomib impairs viability in patient-derived and primary TCL cells. (A) A PTCL, NOS cell line (T8ML-1) and two CTCL cell lines
(H9, MyLa) were cultured with ixazomib (200 nM) or vehicle control for 3 or 24 hour, as indicated. Accumulation of total ubiquitinated pro-
tein and b-catenin were determined in whole cell lysates as a measure of proteasomal inhibition. (B,C) Cell viability was determined by
Annexin V/propidium iodide staining in the cell lines indicated treated with ixazomib (48 hour) at the concentrations shown. Representative
data from at least 3 independently performed experiments is shown. (D) Cell viability was similarly examined ex vivo in purified malignant T
cells obtained from a Sezary Syndrome patient after exposure (24 or 48 hour) to ixazomib at the concentrations shown (10–200 nM). Data
obtained from technical replicates is summarized in the bar graphs shown. (E) Primary malignant T cells purified from independent patients
(n54) were cultured for 48 hour with ixazomib (200 nM) or vehicle control and cell viability similarly determined. (**P< .01, ***P< .001)
[Color figure can be viewed at wileyonlinelibrary.com]
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with currently available agents.2–6 Histone deacetylase (HDAC) inhibi-
tors are approved for use in both CTCL and PTCL. Among 74 patients
with stage Ib-IVA MF/SS treated with vorinostat, a single CR was
observed (1.4%). Patients treated with the approved HDAC inhibitors
romidepsin and belinostat may anticipate CR rates of 15% and 10.8%,
respectively.32,33 Among patients achieving a CR/CRu with romidepsin
(n519), 53% were durable (12 months).34 Pralatrexate, a novel anti-
folate that is efficiently internalized by the reduced folate carrier and
then retained within the cell upon being polyglutamylated, was associ-
ated with a CR rate of 11% in the PROPEL study.35 In contrast to the
PROPEL study which was comprised of largely PTCL patients, a modi-
fied dosing schedule was subsequently identified, and among patients
treated in the expansion cohort of that study (n529), a single CR
(3.4%) was observed.36 In the phase II setting, 69 evaluable CTCL
patients (excluding those with only lymphomatoid papulosis) were
treated with brentuximab vedotin, and a collective CR rate of 19%
observed.37,38 In the recently reported phase III ALCANZA trial, which
randomized patients with CD301 CTCL to either brentuximab vedotin
or a physician’s choice (ie, methotrexate or bexarotene) of therapy,
16% of patients treated with brentuximab vedotin achieved a CR.
While CR rates exceeding 50% are anticipated among ALCL patients
treated with brentuximab vedotin,39 among the more common PTCL
subtypes response rates are more modest, with CR rates of 14% and
38% being observed among PTCL, NOS and AITL patients, respec-
tively.40 Studies using novel combinations of these agents with either
conventional anthracycline-based chemotherapy in the upfront setting
or with other novel agents in the relapsed/refractory setting are
ongoing, and these results are eagerly awaited.
Key regulatory proteins involved in cell growth and survival,
including those conferring resistance to DNA damage or conventional
chemotherapeutic agents, are proteasomal substrates and susceptible
to inhibition of the proteasome. For example, NF-kB activation pro-
motes T-cell lymphomagenesis and confers resistance to chemotherapy
in malignant T cells.13,14,16 GATA-3 expression is not only NF-kB
dependent,16,18 but is also required for the homeostatic survival,18,41
differentiation,42 and migration43 of conventional T-cell subsets. Con-
sistent with its role in conventional T cells, we have previously shown
that GATA-3 is an NF-jB target gene in malignant T cells and confers
their resistance to chemotherapy in a cell-autonomous manner.16 Not
surprisingly, GATA-3 expression has both diagnostic and therapeutic
implications,19,30 and its expression has successfully identified high-risk
PTCL patients who are unlikely to achieve a remission with conven-
tional chemotherapeutic agents.19,44,45 Therefore, the observation that
TABLE 1 Patient characteristics







001 CTCL (SS) M IVA1 Y Y hi N/A N 12
002 CTCL (SS) F IVA1 Y N int N/A N 1
003 CTCL (SS) M IVA1 Y Y hi N/A N 1
004 CTCL (SS) M IVA1 Y Y hi N/A N 1
005 AITL M IVA Y N N/A 2 N 1
006 PTCL, NOS M IIIA N N N/A 1 Y 1
007 AITL M IVA N N N/A 1 N 3
008 ALCL, ALK2 M IVA N Y N/A 3 Y 2
009 ALCL, ALK2 M IVA Y Y N/A 4 N 3
010 AITL F IVA Y Y N/A 4 N 1
011 CTCL (SS) M IVA1 Y Y hi N/A N 2
012 PTCL, NOS F IVA Y Y N/A 4 Y 1
013 CTCL (MF) M IIb Y Y int N/A Y 2
Note: The CTCL International Prognostic Index (CLIPI) for patients with advanced-stage disease is comprised of 5 variables: male gender, age greater
than 60, B1/B2, N2/N3 and visceral metastases. Patients are risk-stratified into low (0–1 risk factors), intermediate (2 risk factors), or high-risk (3 risk
factors) groups. The International Prognostic Index (IPI) was utilized for PTCL risk-stratification and the number of risk factors (age >60, elevated LDH,
ECOG performance status >1, >1 extranodal site of disease, Ann Arbor Stage III/IV) reported.
FIGURE 2 Bar diagram of the response and outcome for patients
(n512) treated with ixazomib. Prog, progression; Wd, patient
withdrew from study; Rel, relapse
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ixazomib led to significant inhibition of both NF-jB and GATA-3 in pri-
mary TCL specimens ex vivo and following one month of treatment in
the single responder treated in this study is noteworthy. In contrast to
this exceptional responder, we failed to observe significant inhibition
of NF-jB and GATA-3 in the remaining patients examined. While the
mechanism(s) for this difference is unknown, it is tempting to speculate
that IjB and/or NF-jB independent mechanisms of NF-kB and GATA-
3 activation, respectively, may be involved. Consistent with our find-
ings, Ravi et al observed that ixazomib induced apoptosis in multiple
TCL cell lines and was associated with widespread changes in gene
expression, including a significant reduction in c-myc expression. While
c-myc expression was not examined in this study, this observation is
noteworthy, as recently performed next-generation sequencing and
molecular profiling studies have implicated c-myc in T-cell lymphoma-
genesis,9 including the GATA-31 subset of PTCL, NOS.30 Therefore,
future studies exploring c-myc as a therapeutic target in these lympho-
mas may be warranted.
Our experience with ixazomib adds to a preexistent, albeit limited,
clinical experience with proteasome inhibition in TCLs. Zinzani et al
treated CTCL patients with single-agent bortezomib in a small phase II
study. Among the 12 evaluable patients, 2 (17%) achieved a CR. Ixazo-
mib is orally bioavailable and has been associated with increased pro-
teasome inhibition and cytotoxicity when compared with bortezomib
in murine NHL models.46 In a phase I study with intravenous ixazomib,
4 PTCL patients were treated, and a single partial response observed.47
In a pharmacokinetic study with oral ixazomib, a single PTCL, NOS
patient was treated and achieved a PR by cycle 8, but subsequently
progressed after 12 months of treatment.48 While CR rate is a more
clinically meaningful endpoint, the ORR was selected as the primary
endpoint in this study. As only a single response, albeit an exceptional
CR, was observed, this study was closed to further accrual at the time
of a prespecified interim analysis for futility. Therefore, it is difficult to
commend single-agent ixazomib in unselected CTCL/PTCL patients,
thus highlighting the need for the identification of predictive bio-
markers that will improve our ability to select the “right treatment” for
the “right patient.” Therefore, it is notable that TNFR2 activates the
noncanonical NF-jB pathway, as either chromosomal gains involving
the TNFR2 locus or recurrent mutations involving a conserved threo-
nine residue within its TRAF2 regulatory domain are observed in 18%
of CTCL.8 Gains effecting the TNFR2 locus are associated with
increased receptor expression, and expression of the recurrent
(Thr377Ile) mutation in Jurkat cells led to increased proteolytic proc-
essing and activation of NF-jB2 p100, and a commensurate increase in
NF-jB target gene expression.8 Loss-of-function studies using CRISPR-
Cas9 technology were employed in cell lines, demonstrating that
TNFR2 expression and NF-kB activation rendered cells more sensitive
to bortezomib. Conversely, cell lines harboring a truncated NF-kB2
mutant which is not subject to IjB-dependent cytoplasmic sequestra-
tion and is observed in 6% of CTCL,8 (reviewed in Ref. 9), were rela-
tively resistant to bortezomib. These findings suggest that examination
of appropriate biomarkers and the genetic landscape in future studies
is certainly warranted, as this approach may improve our understanding
of the mechanisms conferring susceptibility (or resistance) to novel
therapeutic strategies, including proteasome inhibition.
FIGURE 3 Inhibition of NF-jB and GATA-3 expression in an exceptional responder treated with ixazomib (patient 006). (A) PET/CT images
are shown for patient 006 at baseline, at the time of first response (C3D1) and best response (a CR, C5D1). (B) Intranuclear NF-jB (p65)
and GATA-3 expression were determined by immunohistochemistry both at baseline and following one month of ixazomib treatment
(3200)
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Ixazomib was generally well tolerated and was not associated with
significant hematologic toxicity. This is noteworthy, as proteasome
inhibition is synergistic when combined with other agents, including
HDAC inhibitors.49 The extent to which the synergy observed with
these agents and proteasome inhibitors may be attributed to the effect
of proteasome inhibition on the NF-kB/GATA-3 axis, as our findings
may suggest, c-myc,50 or some other proteasome-dependent mecha-
nism, is unknown, but may warrant scrutiny in future studies.
In summary, we have demonstrated that ixazomib significantly
impairs NF-jB activation and downregulates GATA-3 expression in
malignant T cells. In a small and heterogeneous group of patients with
relapsed/refractory PTCL, a single CR was observed. A phase I/II study
combining ixazomib and romidepsin in relapsed/refractory PTCL is
planned.
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